The wildest move on the board belongs to a stock with four good years in the last ten

TGT shows up here as a rejection at the $150 round, which reads like a ceiling until you notice it printed a new 52-week high in the same session — that round number is underneath the stock now, not above it. It's also the only line on the card whose own history at this kind of level has ever amounted to much; everything else sits within a couple of points of a coin flip in both directions.

MRK is the one worth your time. It got shoved back off its 52-week high on the 18th and then cleared both that high and the round number above it the next session, and that is what a three-day range at double the normal looks like from the inside. Before anyone chases it: MRK has spent the last decade being thoroughly average by our own scoring, and average names stretched this far have gone precisely nowhere from here — median +0.03% five days on. The move is the event, not the setup.

The whole week is arranged around Wednesday night's NVDA print, and NVDA is the mildest name on this card — a typical report-day move of 3%, half of what CRWD does on its own number. The two actually worth watching are PDD on Monday, where a miss has historically cost double digits, and CRWD, which has no miss column at all because it has never had one.

Health Care leads both columns, which is rarer than it sounds — usually the three-month winner is cooling off by the time you check the one-month list, and XLV is doing the opposite. Financials are the mirror image: still comfortably second over three months while going flat over the last one, so that move did its work a while ago. And the sector hauling MRK up the acceleration table is the one still accelerating itself.